前瞻性评估68Ga-DOTATATE与18F-DOPA PET扫描在检测引起异位ACTH综合征的肿瘤中的作用
在三级转诊中心前瞻性比较68Ga-DOTATATE、18F-DOPA及常规影像在24例病理和/或生化治愈证实的异位ACTH综合征患者中的表现。DOPA灵敏度高于奥曲肽扫描,与DOTA有重叠;CT在已知功能影像结果时灵敏度最高。DOTA与DOPA互补,应整合入EAS影像策略,但DOPA尚未获FDA批准用于该适应证。
要点
- DOPA灵敏度88%高于奥曲肽扫描31%,与DOTA的79%有重叠。
- CT在已知功能影像结果时灵敏度96%,不知情时为57%。
- CT/MRI联合DOTA和/或DOPA的PPV为89%-100%,灵敏度64%-87%。
核心结论
- DOTA和DOPA通过提高结构影像的灵敏度和检出病灶的PPV改善EAS肿瘤检测,两者互补,应成为EAS影像策略的组成部分;但DOPA目前尚未获FDA批准用于该适应证。
研究设计与样本
- 在三级转诊中心开展的前瞻性比较研究,纳入24例经病理和/或生化治愈证实的神经内分泌肿瘤所致EAS患者。
- 干预包括2014年至2024年间进行的DOTA PET/CT、DOPA PET/CT、CT、MRI、门控心脏CT/MRI和奥曲肽扫描(OCT)。
主要发现
- 功能扫描中,DOPA灵敏度88%(95%CI 67%-97%)高于OCT的31%(95%CI 10%-61%),与DOTA的79%(95%CI 57%-92%)有重叠。
- 结构影像中,CT在已知功能扫描结果解读时灵敏度最高为96%(95%CI 76%-100%),不知情时为57%(95%CI 35%-76%)。
- 心脏CT/MRI的PPV最高,两者均为100%。
- CT/MRI联合DOTA和/或DOPA的PPV为89%-100%,灵敏度为64%-87%,所有CI均有重叠。
- 不含功能扫描的CT联合MRI的PPV为79%、灵敏度为55%,其CI与含DOTA/DOPA的组合有重叠。
临床怎么用
- 作者认为DOTA和DOPA应成为EAS影像策略的组成部分,两者互补。
- 作者指出DOPA目前尚未获FDA批准用于该适应证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Identification of tumors causing ectopic ACTH syndrome (EAS) is challenging. 68Ga-DOTATATE (DOTA) and 18F-DOPA (DOPA) positron emission tomography/computed tomography (PET/CT) scans are promising imaging modalities warranting further evaluation. OBJECTIVE: This work aimed to compare DOTA and DOPA PET/CT performance in detecting ectopic sources of adrenocorticotropin (ACTH). METHODS: A prospective comparison of DOTA, DOPA, and conventional imaging modalities in EAS was conducted at a tertiary referral center. Participants included 24 patients with EAS from neuroendocrine tumors confirmed by pathology and/or biochemical cure. Interventions included DOTA PET/CT, DOPA PET/CT, CT, MRI, gated cardiac CT/MRI, and Octreoscan (OCT) performed between 2014 and 2024. Main outcome measures included sensitivity (Se) and positive predictive value (PPV) for each imaging modality, and 7 combinations thereof, in patients with identified tumors. RESULTS: Of functional scans, Se for DOPA was higher than OCT (Se 88%; 95% CI, 67%-97% vs 31%; 95% CI, 10%-61%) and overlapped DOTA (Se 79%; 95% CI, 57%-92%). Among structural modalities, CT had the highest Se (96%; 95% CI, 76%-100%) when interpreted knowing results of functional scans; Se was 57% (95% CI, 35%-76%) without those data. Cardiac CT/MRI had the highest PPV (100% for each). Combinations of CT/MRI plus DOTA and/or DOPA provided high PPVs (89%-100%) with Se 64% to 87%; all CIs overlapped. Combined CT and MRI without functional scans provided PPV 79% with Se 55%, although CI overlapped with combinations that included DOTA/DOPA. CONCLUSION: DOTA and DOPA improve tumor detection in EAS by increasing Se of structural scans and PPV of detected lesions. The two scans are complementary and should be integral to imaging strategies for EAS. However, DOPA is not currently approved by the Food and Drug Administration for this indication.
引用
- Elenius H, McGlotten R, Hoang CD, et al. Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome. J Clin Endocrinol Metab. 2025. PMID: 40036831. doi:10.1210/clinem/dgaf114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。